Entering text into the input field will update the search result below

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Cowen 41st Annual Health Care Conference (Transcript)

Mar. 03, 2021 6:55 PM ETSarepta Therapeutics, Inc. (SRPT)
SA Transcripts profile picture
SA Transcripts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Cowen 41st Annual Health Care Conference March 3, 2021 2:40 PM ET

Company Participants

Doug Ingram - Chief Executive Officer

Conference Call Participants

Ritu Baral - Cowen and Company

Ritu Baral

Hey, everyone. Thanks for joining us at the Sarepta fireside chat at the Cowen 2021 Health Care Conference. Hopefully, our first and only virtual health care conference for Cowen.

With us from Sarepta, we have CEO, Doug Ingram; CFO, Ian Estepan; and CMO, Gilmore O'Neill, who I'm sure most of you know.

Question-and-Answer Session

Q - Ritu Baral

So, Doug, let's get started. I guess, Doug and Gilmore. So the last major milestone you have is the top line for the Phase 2 102 study from your DMD gene therapy. So you missed on the top line NSAA analysis, because of some pretty significant baseline imbalances between age cohorts, which were not stratified for baseline lock.

One question I've gotten from investors is why didn't you stratify? And if you could from there, just tell us how you're doing? What's the latest from the crossover patients and how they've been treated?

Doug Ingram

Yes. So a couple of thoughts on that, and you're going to hear a hint of defensiveness I suppose in this question -- in the answer to the question. Look, Sarepta has an enormous amount of experience with the knowledge about Duchenne muscular dystrophy.

And it actually was us that had signaled that in this -- what would have seemed like a fairly tight age range, four to seven years old, there would basically be two populations, a four to five-year old population and a six to seven-year old population.

And I think you know that Ritu, because we've talked about this many times in the past about that. And that's why we built, not

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.